A Study of Subcutaneous Blinatumomab Administration in Participants With R/R and MRD+ B-ALL

ClinicalTrials.gov ID: NCT04521231

Public ClinicalTrials.gov record NCT04521231. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 8:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Open-label Study to Investigate the Safety, Efficacy, and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL) and Minimal Residual Disease Positive (MRD+) B-ALL

Study identification

NCT ID: NCT04521231
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Amgen; Industry
Enrollment: 281 participants

Conditions and interventions

Conditions

B Cell Precursor Acute Lymphoblastic Leukemia

Interventions

Blinatumomab Drug

Drug

Eligibility (public fields only)

Age range: 12 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 3, 2021
Primary completion: Nov 23, 2027
Completion: May 24, 2029
Last update posted: Apr 30, 2026

2021 – 2029

United States locations

U.S. sites: 13
U.S. states: 10
U.S. cities: 13

Facility	City	State	ZIP	Site status
University of California San Francisco Fresno at Community Cancer Institute	Clovis	California	93611	Recruiting
City of Hope National Medical Center	Duarte	California	91010	Recruiting
University of Illinois Chicago	Chicago	Illinois	60612	Recruiting
Johns Hopkins University	Baltimore	Maryland	21287	Recruiting
C.S. Mott Children's Hospital - University of Michigan	Ann Arbor	Michigan	48109	Recruiting
Roswell Park Comprehensive Cancer Center	Buffalo	New York	14263	Recruiting
New York University Grossman School of Medicine and New York University Langone Hospitals	New York	New York	10016	Recruiting
Albert Einstein College of Medicine - Montefiore Medical Center	The Bronx	New York	10467	Recruiting
Childrens Hospital of Philadelphia	Philadelphia	Pennsylvania	19104	Recruiting
St Jude Childrens Research Hospital	Memphis	Tennessee	38105	Recruiting
University of Texas MD Anderson Cancer Center	Houston	Texas	77030	Recruiting
Fred Hutchinson Cancer Center	Seattle	Washington	98109-1023	Completed
The Medical College of Wisconsin	Milwaukee	Wisconsin	53226	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 94 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT04521231, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Apr 30, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT04521231 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →